Alpha-1-antitrypsin Deficiency: Biology, Diagnosis, Clinical Significance, and Emerging Therapies is the authoritative reference on AATD, providing standards for diagnosis, monitoring, treatment and appropriate avenues of research.
The book covers the disease from basic biology and epidemiology, to clinical impact, and includes the understanding of the natural history of the disease and the significant advances that have been made in the last 20 years, including the three-dimensional structure of the molecule, its broad biological activity and improved therapeutic options, including replacement therapy and gene therapy.
The editors have recruited international experts in the field to contribute evidence-based chapters and insights on future developments in the understanding of this disease.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
2. The Swedish AAT screening study: What we have learnt-from birth through to young middle age
3. Gene regulation
4. AAT variants
5. AAT structure and function
6. Novel biological functions of A1AT
7. AATD and lung disease
8. Alpha-1-Antitrypsin Deficiency Liver Disease
9. AATD epidemiological studies and other AATD associated diseases
10. THORACIC CT IMAGING IN AATD
11. Animal models of alpha-1 antitrypsin deficiency
12. Establishing European Registries for AATD and clinical trials for lung disease
13. Establishing the USA Registry: logistics, impact and early clinical trials
14. Gene therapy
15. The future of AAT research
Professor Kalsheker is the Head of Division and Co-director of the Institute of Genetics and teaches in the School of Life Sciences at the University of Nottingham. His work is focused on the study of humoral control of genes of the serine proteinase inhibitor family which regulate key biological pathways and how functional genetic variants contribute to complex diseases such as chronic lung disease.
Robert Andrew Stockley Professor of Medicine, Birmingham University; Director of Research and Development, University Hospital Birmingham NHS Foundation Trust; Medical Director, Lung Resource Centre, Queen Elizabeth Hospital Birmingham Birmingham, UK.
Professor Stockley has a longstanding interest in chronic obstructive pulmonary disease (COPD) with special reference to airway inflammation, proteinases and anti-proteinases, and especially the role of the neutrophils, bacteria and exacerbations. His research focuses on investigating the factors governing neutrophil differentiation, activation and recruitment as processes that determine the degree of tissue damage resulting in the establishment and progression of chronic lung disease.